Guidelines on the Treatment with Integrated Traditional Chinese Medicine and Western Medicine for Severe Coronavirus Disease 2019

Overview

Journal Pharmacol Res

Publisher Elsevier

Specialty Pharmacology

Date 2021 Oct 29

PMID 34715330

Citations 12

Authors

Zhi-yu Li

Zhi-Jun Xie

Hai-Chang Li

Jian-Jian Wang

Xiang-Hui Wen

Shou-Yuan Wu

Jiao Chen

Juan-Juan Zhang

Lin Li

Qiang-Qiang Guo

Qiu-Ping Liu

Hui Lan

Yue-Peng Jiang

Dian-Ming Li

Xiao-Feng Xu

Si-Yue Song

Ming Zhang

Shan Fang

Wei-Dong Lai

Yi-Ni Gao

Feng-Qi Zhang

Wen-Qing Luo

Yu Lou

Wu Chen

Xia-Feng Zhang

Ke-Er Wang

Ming-Qian Zhou

Yuan-Fang He

An-Ran Xi

Yan Gao

Yi Zhang

Yao-Long Chen

Cheng-Ping Wen

Affiliations

Soon will be listed here.

Abstract

Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT).

Citing Articles

Clinical practice guidelines and expert consensus statements on rehabilitation for patients with COVID-19: a systematic review.

Zhang Y, Li Y, Zhong D, Li H, Liu X, Tang W BMJ Open. 2024; 14(9):e086301.

PMID: 39260851 PMC: 11409320. DOI: 10.1136/bmjopen-2024-086301.

Comprehensive consideration of multiple determinants from evidence to recommendations in guidelines for most traditional Chinese medicine was suboptimal: a systematic review.

Gao Y, Cao R, Liu Z, Liao Y, Tao L, Feng Y BMC Complement Med Ther. 2024; 24(1):19.

PMID: 38178118 PMC: 10765706. DOI: 10.1186/s12906-023-04321-0.

Chinese herbal medicine and COVID-19: quality evaluation of clinical guidelines and expert consensus and analysis of key recommendations.

Zheng Q, Gao Y, Xiong L, Huang H, Li J, OuYang G Acupunct Herb Med. 2023; 2(3):152-161.

PMID: 37808348 PMC: 9746251. DOI: 10.1097/HM9.0000000000000043.

Clinical Study on the Emotional Intervention of Patients with Asymptomatic and Mild Novel Coronavirus (COVID-19).

Lu B, Shi W, Zhou X, Fu D, Duan L, He X Medicina (Kaunas). 2023; 59(5).

PMID: 37241127 PMC: 10224050. DOI: 10.3390/medicina59050895.

Effects of diarylbutane lignans from fruit on SARS-CoV-2 3CL and PL and their anti-inflammatory properties.

Li B, Qiao L, Xiao Q, Zhang J, Liu J, Zhang B Phytomed Plus. 2023; 3(2):100432.

PMID: 36968623 PMC: 10005971. DOI: 10.1016/j.phyplu.2023.100432.

References

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Tian J, Yan S, Wang H, Zhang Y, Zheng Y, Wu H . Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study. Pharmacol Res. 2020; 161:105127. PMC: 7416080. DOI: 10.1016/j.phrs.2020.105127. View

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270):220-232. PMC: 7833295. DOI: 10.1016/S0140-6736(20)32656-8. View

Kung J, Miller R, Mackowiak P . Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress. Arch Intern Med. 2012; 172(21):1628-33. DOI: 10.1001/2013.jamainternmed.56. View

Bian Y, Qi W, Song Q . [Evaluation on effect of integrative medical treatment on quality of life of rehabilitation stage in 85 patients with SARS]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003; 23(9):658-60. View

He S, Tian J, Li X, Zhou Y, Xiao M, Zhang Y . Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study. Front Pharmacol. 2020; 11:549117. PMC: 7577046. DOI: 10.3389/fphar.2020.549117. View

Hermine O, Mariette X, Tharaux P, Resche-Rigon M, Porcher R, Ravaud P . Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):32-40. PMC: 7577198. DOI: 10.1001/jamainternmed.2020.6820. View

Guo H, Zheng J, Huang G, Xiang Y, Lang C, Li B . Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. Ann Palliat Med. 2020; 9(5):3235-3248. DOI: 10.21037/apm-20-1478. View

Libster R, Marc G, Wappner D, Coviello S, Bianchi A, Braem V . Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021; 384(7):610-618. PMC: 7793608. DOI: 10.1056/NEJMoa2033700. View

10.

Shea B, Hamel C, Wells G, Bouter L, Kristjansson E, Grimshaw J . AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009; 62(10):1013-20. DOI: 10.1016/j.jclinepi.2008.10.009. View

11.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

12.

Wang Q, Shi G, Zhang Y, Lu F, Xie D, Wen C . Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Sci Rep. 2019; 9(1):355. PMC: 6344516. DOI: 10.1038/s41598-018-36314-2. View

13.

Elsawah H, Elsokary M, Elrazzaz M, Elshafie A . Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. J Med Virol. 2020; 93(3):1265-1275. PMC: 7461373. DOI: 10.1002/jmv.26442. View

14.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

15.

Pang W, Liu Z, Li N, Li Y, Yang F, Pang B . Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis. Integr Med Res. 2020; 9(3):100477. PMC: 7385501. DOI: 10.1016/j.imr.2020.100477. View

16.

Schunemann H, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R . Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2013; 186(3):E123-42. PMC: 3928232. DOI: 10.1503/cmaj.131237. View

17.

Chen Y, Yang K, Marusic A, Qaseem A, Meerpohl J, Flottorp S . A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2016; 166(2):128-132. DOI: 10.7326/M16-1565. View

18.

Reina-Gutierrez S, Torres-Costoso A, Martinez-Vizcaino V, Nunez de Arenas-Arroyo S, Fernandez-Rodriguez R, Pozuelo-Carrascosa D . Effectiveness of Pulmonary Rehabilitation in Interstitial Lung Disease, Including Coronavirus Diseases: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2021; 102(10):1989-1997.e3. PMC: 8474048. DOI: 10.1016/j.apmr.2021.03.035. View

19.

Tang X, Feng Y, Ni J, Zhang J, Liu L, Hu K . Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021; 100(2):116-126. PMC: 7900459. DOI: 10.1159/000512063. View

20.

Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L . High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front Immunol. 2021; 12:627844. PMC: 7933558. DOI: 10.3389/fimmu.2021.627844. View